{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.1","value":"21.7"},{"groupId":"OG001","spread":"5.7","value":"21.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Physical Well-being Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.7","value":"19.0"},{"groupId":"OG001","spread":"5.5","value":"21.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.9","value":"20.1"},{"groupId":"OG001","spread":"5.2","value":"21.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.2","value":"20.4"},{"groupId":"OG001","spread":"6.1","value":"21.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.1","value":"20.2"},{"groupId":"OG001","spread":"6.3","value":"21.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.5","value":"19.9"},{"groupId":"OG001","spread":"6.6","value":"22.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.9","value":"20.5"},{"groupId":"OG001","spread":"6.2","value":"22.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.6","value":"20.8"},{"groupId":"OG001","spread":"6.1","value":"22.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.7","value":"21.3"},{"groupId":"OG001","spread":"7.2","value":"20.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.5","value":"21.8"},{"groupId":"OG001","spread":"8.4","value":"20.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Physical Well-being Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.7","value":"17.8"},{"groupId":"OG001","spread":"7.4","value":"19.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Physical Well-being Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.5","value":"19.6"},{"groupId":"OG001","spread":"4.7","value":"23.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Physical Well-being Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.8","value":"20.7"},{"groupId":"OG001","spread":"4.9","value":"20.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Social Well-being Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.6","value":"20.0"},{"groupId":"OG001","spread":"5.0","value":"20.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Social Well-being Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.1","value":"19.7"},{"groupId":"OG001","spread":"4.4","value":"20.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Social Well-being Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.6","value":"20.3"},{"groupId":"OG001","spread":"4.6","value":"20.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Social Well-being Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.5","value":"20.3"},{"groupId":"OG001","spread":"5.0","value":"21.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Social Well-being Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.0","value":"20.7"},{"groupId":"OG001","spread":"4.9","value":"21.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Social Well-being Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.6","value":"20.6"},{"groupId":"OG001","spread":"4.8","value":"21.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Social Well-being Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.9","value":"20.0"},{"groupId":"OG001","spread":"5.1","value":"21.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Social Well-being Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.4","value":"20.5"},{"groupId":"OG001","spread":"5.4","value":"20.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Social Well-being Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.1","value":"20.0"},{"groupId":"OG001","spread":"5.0","value":"22.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Social Well-being Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.7","value":"19.3"},{"groupId":"OG001","spread":"4.5","value":"20.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.3","value":"20.5"},{"groupId":"OG001","spread":"4.9","value":"21.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.1","value":"16.1"},{"groupId":"OG001","spread":"5.0","value":"15.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"title":"Emotional Well-being Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.7","value":"16.5"},{"groupId":"OG001","spread":"4.7","value":"16.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.2","value":"17.2"},{"groupId":"OG001","spread":"4.1","value":"17.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.4","value":"17.3"},{"groupId":"OG001","spread":"3.9","value":"17.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.3","value":"17.3"},{"groupId":"OG001","spread":"4.8","value":"18.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.4","value":"16.9"},{"groupId":"OG001","spread":"4.9","value":"18.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.8","value":"17.4"},{"groupId":"OG001","spread":"4.6","value":"18.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.1","value":"17.5"},{"groupId":"OG001","spread":"3.2","value":"19.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.8","value":"18.1"},{"groupId":"OG001","spread":"3.6","value":"17.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.2","value":"18.3"},{"groupId":"OG001","spread":"5.8","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Emotional Well-being Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.9","value":"14.5"},{"groupId":"OG001","spread":"5.6","value":"15.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Emotional Well-being Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.4","value":"15.4"},{"groupId":"OG001","spread":"4.7","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Emotional Well-being Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.0","value":"18.0"},{"groupId":"OG001","spread":"6.5","value":"18.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Functional Well-being Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.2","value":"16.2"},{"groupId":"OG001","spread":"6.0","value":"18.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.7","value":"16.9"},{"groupId":"OG001","spread":"5.8","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.3","value":"17.4"},{"groupId":"OG001","spread":"5.8","value":"17.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.7","value":"17.5"},{"groupId":"OG001","spread":"6.1","value":"18.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.3","value":"17.5"},{"groupId":"OG001","spread":"7.4","value":"19.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.0","value":"18.0"},{"groupId":"OG001","spread":"6.3","value":"19.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.3","value":"17.0"},{"groupId":"OG001","spread":"6.6","value":"20.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.7","value":"18.3"},{"groupId":"OG001","spread":"6.1","value":"18.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.4","value":"18.7"},{"groupId":"OG001","spread":"5.8","value":"19.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Functional Well-being Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.0","value":"15.0"},{"groupId":"OG001","spread":"7.0","value":"17.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Functional Well-being Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.1","value":"16.5"},{"groupId":"OG001","spread":"6.5","value":"18.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Functional Well-being Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.4","value":"38.0"},{"groupId":"OG001","spread":"6.0","value":"39.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.5","value":"36.2"},{"groupId":"OG001","spread":"6.4","value":"37.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.1","value":"35.9"},{"groupId":"OG001","spread":"5.9","value":"37.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.6","value":"35.1"},{"groupId":"OG001","spread":"6.1","value":"36.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.8","value":"35.2"},{"groupId":"OG001","spread":"7.5","value":"36.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.2","value":"35.6"},{"groupId":"OG001","spread":"5.9","value":"37.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.1","value":"35.1"},{"groupId":"OG001","spread":"7.9","value":"37.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.3","value":"35.9"},{"groupId":"OG001","spread":"7.4","value":"37.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.4","value":"36.6"},{"groupId":"OG001","spread":"7.1","value":"35.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.7","value":"37.5"},{"groupId":"OG001","spread":"8.8","value":"34.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.8","value":"34.6"},{"groupId":"OG001","spread":"7.3","value":"36.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.0","value":"34.7"},{"groupId":"OG001","spread":"7.5","value":"37.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Neurotoxicity Subscale Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.6","value":"78.0"},{"groupId":"OG001","spread":"15.3","value":"78.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.4","value":"71.5"},{"groupId":"OG001","spread":"15.2","value":"77.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.5","value":"72.9"},{"groupId":"OG001","spread":"14.2","value":"76.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.0","value":"72.8"},{"groupId":"OG001","spread":"16.1","value":"75.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.7","value":"72.9"},{"groupId":"OG001","spread":"17.4","value":"76.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.8","value":"73.3"},{"groupId":"OG001","spread":"18.0","value":"80.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.4","value":"74.1"},{"groupId":"OG001","spread":"17.6","value":"79.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.9","value":"74.4"},{"groupId":"OG001","spread":"17.1","value":"80.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.5","value":"77.2"},{"groupId":"OG001","spread":"16.4","value":"74.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.2","value":"77.9"},{"groupId":"OG001","spread":"20.9","value":"74.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.5","value":"67.5"},{"groupId":"OG001","spread":"18.0","value":"72.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Trial Outcome Index Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.5","value":"70.8"},{"groupId":"OG001","spread":"15.7","value":"79.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Trial Outcome Index Score at 30-Day Safety Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"description":"FACT/GOG-NTX questionnaire consists of questions for dimensions related to physical, social, emotional, and functional well-being which contains 11 items, with responses scored on a Likert scale from 0 (not at all) to 4 (very much) designed to capture the symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The summed scores of each item were reverted into standardized scores ranging from 0 to 44, with a higher score indicating a lower level of neurological toxicity and less effect on quality of life (ie, higher scores indicate better quality of life). The trial outcome index consists of two subscales from the FACT-G: Physical Well Being (7 items) and Functional Well Being (7 items), plus the Cervix Cancer-specific subscale (15 items). Each item in the trial outcome index scored using a 5-point scale (0=not at all to 4=very much). The summed scores of each item were reverted into standardized scores ranging from 0 to 116. Higher scores indicate better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an oral dose of 45 milligram (mg) of MEK162 tablets (3 tablets of 15 mg) twice daily for each 28-day treatment cycle until disease progression, withdrawal of consent, initiation of subsequent anticancer therapy, lost to follow-up or death, whichever occurred first. Participants were followed up to 30 days after last dose of study intervention.","id":"OG000","title":"MEK 162"},{"description":"Participants received chemotherapies as per treating physician's choice in accordance to the institutional standard of care. Participants received one of the three intravenous (IV) infusion therapies: Liposomal doxorubicin 40 milligram per meter square (mg/m\\^2) on Day 1 of each 28-day cycle or Paclitaxel 80 mg/m\\^2 on Days 1, 8, and 15 of each 28-day cycle or, Topotecan 1.25 mg/m\\^2 on Days 1 through 5 of each 21-day cycle. Participants were followed up to 30 days after last dose of study intervention.","id":"OG001","title":"Physician's Choice"}],"paramType":"MEAN","populationDescription":"Analysis population included all randomized participants (228 participants in MEK162 group, 113 participants in physician's choice group).","reportingStatus":"POSTED","timeFrame":"Screening, every 8 weeks from randomization for the first 72 weeks (while on treatment), treatment discontinuation visit, 30-day safety follow-up visit","title":"Quality of Life Per Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX)","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}